In Brief: Hoechst-Roussel's Altace (ramipril)
Hoechst-Roussel's Altace (ramipril): ACE inhibitor is "approvable" May 26 for the new indication of congestive heart failure treatment following MI. The Altace supplemental NDA is based on the 2,006-patient Acute Infarction Ramipril Efficacy (AIRE) trial, which found a 27% risk reduction in all-cause mortality for Altace compared to placebo when the drug was given on days three to 10 following a myocardial infarction...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth